about
Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteersAffinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets.Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusionPlatelet adhesion receptors: novel targets for anti-thrombotic therapy.Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit.The interaction of thrombin with blood platelets.The Marine-Derived Kinase Inhibitor Fascaplysin Exerts Anti-Thrombotic ActivityNanoparticles and the blood coagulation system. Part I: benefits of nanotechnology.A molecular basis for affinity modulation of Fab ligand binding to integrin alphaIIb beta3.Integrin αIIbβ3 outside-in signaling.Bio-inspired nanomedicine strategies for artificial blood components.In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes.The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flankiProteolytic degradation of the RGD-binding and non-RGD-binding conformers of human platelet integrin glycoprotein IIb/IIIa: clues for identification of regions involved in the receptor's activationInteractions of integrin GPIIb/IIIa-derived peptides with fibrinogen investigated by NMR spectroscopy.Red cell ICAM-4 is a novel ligand for platelet-activated alpha IIbbeta 3 integrin.A novel approach to the design of potent bioactive peptides by incorporation of proline brackets: antiplatelet effects of Arg-Gly-Asp peptides.Integrin expression is upregulated during early healing in a canine intrasynovial flexor tendon repair and controlled passive motion model.Low-density lipoprotein specifically binds glycoprotein IIb/IIIa: a flow cytometric method for ligand-receptor interaction.Cell adhesive peptides functionalized on CoCr alloy stimulate endothelialization and prevent thrombogenesis and restenosis.
P2860
Q28193315-2DD57ED1-6D8C-44E8-B86F-CC069E8B3EC1Q33314508-349A1F28-A22F-4555-8EB1-764FE215301FQ33490246-0760A4E1-E1BA-4217-ABCE-88E499672AFCQ33951293-2F3C7F6C-3129-47C0-A304-D3E11F84F6F3Q35925710-7DD7862A-6B62-42EC-B093-21E515107987Q36291249-39B0C6D3-1942-4F93-A5F6-C41E2DBBB53FQ36329699-02495843-D014-484F-90CF-13D1BA05CFADQ38105137-80BCAE7A-AC96-4DB6-BAC8-1386673E385DQ38353931-CC811212-3ECE-4C60-B173-1FCF9994CD99Q38644725-E37D5CE3-C94E-4DD7-816F-8FC76B724D81Q39179984-F43A844E-05BF-4A9B-8EBF-21BC7C0A7C20Q40025769-D8310D6B-ACB0-4B3C-9E68-BF7C0ABABC6EQ41941084-9F8D1777-6FEC-4AD6-BB07-9AE4BE007835Q42833444-126AA30F-CD5E-484B-9EF1-AD395E2EE428Q42981591-EBB38B18-216B-4F61-A1E0-A104F5605820Q44246029-ECBE5B4C-FDE1-4A8D-948F-2FC8B52C5EB7Q45080636-DCF54D72-7E87-421C-B3FC-119931D06914Q46272193-627C9047-8879-4082-BBCF-01D69A5AAF7CQ46832236-DCB9BE7B-15DD-471C-80D8-8713450CD822Q48892744-DC4D37EB-1614-467C-8CE3-12134A437AFF
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Ligand binding to GPIIb-IIIa: a status report.
@ast
Ligand binding to GPIIb-IIIa: a status report.
@en
type
label
Ligand binding to GPIIb-IIIa: a status report.
@ast
Ligand binding to GPIIb-IIIa: a status report.
@en
prefLabel
Ligand binding to GPIIb-IIIa: a status report.
@ast
Ligand binding to GPIIb-IIIa: a status report.
@en
P2093
P356
P1476
Ligand binding to GPIIb-IIIa: a status report.
@en
P2093
P304
P356
10.1055/S-2007-1002571
P577
1992-01-01T00:00:00Z